Exchange: NASDAQ·Updated 12:39 PM EDT
News
all
press releases
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.read more...
Benzinga
More News
What Insmed Stock's Premium Is Actually Buying
What Insmed Stock's Premium Is Actually Buying...
Yahoo! Finance: News
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Zacks
Insmed Stock Jumps 33% Despite Narrower Q2 Loss
(RTTNews) - Insmed Incorporated (INSM) shares surged $32.83, or 33.16 percent, to $131.85 on Thursday, after the biopharmaceutical company reported a sharply narrower second-quarter loss, strong product revenue growth, and raised its full-year outlook for Brinsupri...
Nasdaq News: Markets
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.read more...
Benzinga
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of +24.64% and +9.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., Aug. 6, 2026 Total Company Revenues of $425.5 Million for the Second Quarter of 2026BRINSUPRI...
PR Newswire
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Here's Why Baron Health Care Fund Remains Bullish on Insmed (INSM)
Here's Why Baron Health Care Fund Remains Bullish on?Insmed?(INSM...
Yahoo! Finance: News

Advertisement|Remove ads.